



PRESS RELEASE

to-BBB signs agreement with Genmab on 2B-Trans™ technology

Leiden, The Netherlands - May 24, 2005 - The Dutch biotechnology company to-BBB announced today that it has signed an evaluation and licence option agreement on to-BBB's drug targeting technology 2B-Trans™ with Genmab A/S (Copenhagen, Denmark) (CSE: GEN). With the 2B-Trans™ technology it is possible to deliver drugs to the brain.

Genmab will evaluate to-BBB's technology as a means of delivering Genmab's human monoclonal antibodies across the blood-brain barrier to enable immunotherapeutic approaches in brain cancer and inflammation in the brain. Under the terms of the agreement, Genmab will have an option on a licence to use the 2B-Trans™ technology for up to two Genmab therapeutic antibodies. Genmab will bear all costs during development and to-BBB will receive milestone payments and royalties on net sales of brain-targeted antibody products. Further financial details were not disclosed.

"We are pleased to work with to-BBB in this area as antibodies usually only poorly penetrate the brain. The technology provided by to-BBB may open up new opportunities for select human therapeutic antibodies", says Professor Jan van de Winkel, Executive Vice President & Chief Scientific Officer of Genmab.

to-BBB is delighted with the collaboration with Genmab: "The agreement is an important step for to-BBB to show its potential in the treatment of brain cancer and inflammation in the brain with therapeutic antibodies", says Dr. Pieter Gaillard, Chief Executive Officer of to-BBB.



About 2B-Trans™ technology

The central nervous system (CNS) drug market is a rapidly growing market with many unmet medical needs. However, many potential CNS drugs cannot enter the brain due to the presence of the neuroprotective blood-brain barrier. to-BBB developed the unique CNS drug targeting solution 2B-Trans™ that delivers drugs into the CNS after an intravenous injection, without disruption of the blood-brain barrier. The proprietary 2B-Trans™ technology uses a well characterized and effective transport system with a specific carrier protein that has an excellent proven safety profile in humans.

About to-BBB technologies BV

to-BBB, founded in 2003, is a spin-off company from the renowned Blood-Brain Barrier Research Group of Leiden University in The Netherlands. to-BBB is located at the Bio-Science Park in Leiden.

to-BBB has recently announced a collaboration agreement with Biogen Idec (NASDAQ: BIIB) and has signed a research agreement with another undisclosed US based top 5 biotech company. to-BBB is currently negotiating agreements with several other companies, who will be offered access to the 2B-Trans™ technology. For additional information about the company, please visit www.toBBB.com.

For further information please contact:

Alfred N. Nijkerk, PharmD, CBO

Tel: +31 6 55128387

Fax: +31 84 8709728

E-mail: Nijkerk@toBBB.com

Website: www.toBBB.com